Acorda commences AMPYRA clinical research for post-stoke deficits Acorda Therapeutics.

Exploratory efficacy final result measures will include: changes in walking speed, lower and upper extremity engine and sensory function, manual dexterity, assessment of functional independence in performing activities of daily living, and clinician and subject global impressions of general improvement. The analysis is expected to include approximately 66 people who have experienced an ischemic stroke at least half a year prior to enrollment, by which time the deficits are stable generally. The ongoing company expects to announce initial study results in early 2013..Congress does not approve legislation preventing 21 percent cut in obligations for physicians The American Academy of Dermatology Association is disappointed that america Congress has failed to approve legislation preventing the implementation of a 21 % cut in payments for physicians who treat Medicare patients. ‘For more than a decade, the AADA has been advocating that Congress repeal the flawed sustainable development rate formula rather than continue to use temporary extensions,’ stated dermatologist David M.